Navigation Links
New Generation Disinfecting Products to be Launched in Direct Sales Channel
Date:5/24/2010

DALLAS, May 24 /PRNewswire/ -- An innovative family of EPA-registered disinfecting products will be launched through a new direct selling company, it was announced today.

The first product, IV-7 Ultimate Germ Defense™, is a revolutionary, patented, broad-spectrum germ-killing treatment for hard surfaces.  It kills viruses, bacteria and fungi in as quickly as 30 seconds, using the first new disinfectant technology approved by the EPA in 30 years.

IV-7 has no odor or fumes, does not cause skin irritation, and creates an invisible barrier of protection that continues killing germs for 24 hours.  

It will be brought to the consumer market through a new direct selling company called IV-7 Direct, using a multi-level sales model.  Independent sales representatives will earn commissions selling the product and also from the sales of people who they enlist into the business.

John Rochon, former chairman of Mary Kay Inc. and a veteran of over 20 years in the direct selling industry, is heading IV-7 Direct, which is part of Dallas-based Richmont Holdings.  A related company, Richmont Sciences, is the sales and marketing arm of IV-7's manufacturer, Pure Biosciences of San Diego ( PURE).  

"We have an obligation to get this product into the war on germs as quickly as possible, to protect our loved ones and save lives," said Mr. Rochon.

"IV-7 is too special to put on store shelves.  Through the person-to-person contact of direct selling, we can show consumers how these products are different and spread the word quickly."  

"When I decided to return to the direct selling industry, I wanted to approach it in a new way.  I wanted a new business model that did two things:  First, get this product into the hands of millions of people quickly without a multi-million dollar advertising campaign; Second, give sellers a unique binary and unilevel compensation plan that can replenish the savings they've lost in the recession."

IV-7's patented formula is powered by silver dihydrogen citrate (SDC), which has been proven effective against viruses, bacteria and fungi including H1N1, MRSA, Salmonella, E. coli, Norovirus, Influenza A, VRE, Campylobachter jejuni, Staphylococcus aureus and other pathogens.  

PURE is developing additional uses for SDC in areas such as personal care products, pharmaceuticals and food processing.  Additional products will be added to the IV-7 Direct lineup.


'/>"/>
SOURCE IV-7 Direct
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Volcano Announces Positive Clinical Experience With Its Second Generation OCT Catheter, Prepares for U.S. Regulatory Study
2. Quantum move toward next generation computing
3. Haydon Kerk Motion Solutions Inspires Next Generation of Innovators as Silver Supplier of the FIRST Robotics Competition
4. Argonne to host next generation battery symposium May 3-4
5. Cerealus Announces Licensing Agreement for Bio-Based Ceregel™, A Next Generation Strength and Retention System
6. Ambry Genetics Launches First X-Linked Mental Retardation Diagnostics Using Next Generation Sequencing
7. OriGene Technologies Raises $16 Million to Build the Largest Collection of Next Generation Monoclonal Antibodies (TrueMAB(TM)) to Cover the Majority of Human Proteome
8. Acologix Presents Data on Cartilage Regeneration by AC-100 at the 56th Annual Meeting of the Orthopaedic Research Society
9. Caliper Life Sciences Launches LabChip(R) XT for Next Generation Sequencing Applications
10. GenomeQuest Announces Boston Seminar: Sequence Data Management for Next Generation Sequencing
11. Wellcome Trust Sanger Institute to use NEBNext(TM) DNA Sample Preparation Reagents from New England Biolabs for Next Generation Sequencing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... MedGenome,s Commitment Will Help ... of Complex Diseases Such as Cancer, Metabolic Disorders, ... --> --> MedGenome, the market ... leading provider of genomics research services globally, today ... GenomeAsia 100K consortium as a founding member. ...
(Date:2/11/2016)...  Vermillion, Inc. (NASDAQ: VRML ), a bio-analytical ... formation of the Steering Committee for its Pelvic Mass ... Pelvic masses can present physicians and healthcare professionals ... is ruled out, pelvic masses may include cancers of ... ovarian tumors and gastrointestinal and urinary tract masses. ...
(Date:2/11/2016)... , Feb. 11, 2016  Spectra BioPharma Selling Solutions ... that provides biopharma companies the experience, expertise, operational ... deploy outsourced sales teams. Created in concert with ... both the strategic and tactical needs of its ... solutions through both personal and non-personal promotion. ...
(Date:2/11/2016)... SANTA CRUZ, Calif. , Feb. 11, 2016 /PRNewswire/ ... accepting applications to its beta program for a planned ... co-founder, will present the company,s metagenomic genome assembly method ... 2016 Advances in Genome Biology & Technology conference in ... novo  assembly of these highly complex datasets is difficult. ...
Breaking Biology Technology:
(Date:2/9/2016)... Calif. , Feb. 9, 2016 Vigilant Solutions ... license plate reader (LPR) to develop a lead in a ... commercially available LPR data to locate the suspect vehicle. Due ... of the case have been omitted at the agency,s request. ... for the agency explains, "Our victim was found deceased at ...
(Date:2/5/2016)... DUBLIN , Feb. 5, 2016 /PRNewswire/ ... the addition of the "Global Facial ... offering. --> http://www.researchandmarkets.com/research/5kvw8m/global_facial ) has ... Facial Recognition Market 2016-2020" report to ... Markets ( http://www.researchandmarkets.com/research/5kvw8m/global_facial ) has announced the ...
(Date:2/3/2016)... --> --> Fourth quarter ... up 1,187% compared with fourth quarter of 2014. Gross margin ... (loss: 30.0). Earnings per share increased to SEK 6.39 (loss: ... (neg: 74.7). , --> --> ... 2,900.5 M (233.6), up 1,142% compared with 2014. Gross margin ...
Breaking Biology News(10 mins):